Michael G Hanna
Overview
Explore the profile of Michael G Hanna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
283
Citations
4471
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salam S, Morrow J, McDermott M, Zafeiropoulos N, Thornton J, Shah S, et al.
Clin Exp Rheumatol
. 2025 Feb;
43(2):334-344.
PMID: 40018748
Objectives: To investigate the intramuscular effects of arimoclomol using quantitative magnetic resonance imaging (qMRI) of the thighs in a subset of inclusion body myositis (IBM) participants from a multicentre, randomised,...
2.
Salam S, Morrow J, Shah S, Hanna M, Dimachkie M, Machado P
Clin Exp Rheumatol
. 2025 Feb;
43(2):372-378.
PMID: 39977010
Inclusion body myositis (IBM) is an acquired myopathy belonging to the spectrum of idiopathic inflammatory myopathies. It commonly presents in individuals aged above 50 years of age. Characteristic clinical features...
3.
Schoonen M, Fassad M, Patel K, Bisschoff M, Vorster A, Makwikwi T, et al.
Eur J Hum Genet
. 2025 Feb;
PMID: 39966651
King-Denborough Syndrome (KDS) is a congenital myopathy (CM) characterised by myopathy, dysmorphic features and susceptibility to malignant hyperthermia. The objective of this study was to investigate the genotype-phenotype correlation in...
4.
Evans M, Salhab H, Sinclair C, Shah S, Hanna M, Yousry T, et al.
Ann Clin Transl Neurol
. 2025 Feb;
PMID: 39957630
Objective: We measured clinical and quantitative MRI outcome measures in CMT1A to assess long-term responsiveness, establish longitudinal validity and assess MRI as a bridging biomarker. Methods: Twenty patients with CMT1A...
5.
Ala P, Torelli S, Ahmed A, Reilly M, Hanna M, Muntoni F, et al.
Neuromuscul Disord
. 2025 Feb;
48:105280.
PMID: 39933206
Neuromuscular diseases are either inherited or acquired conditions that cause muscle wasting and weakness and sensory loss in some forms, which result in disability and in some cases reduced survival....
6.
Zhu C, Han Y, Byun J, Xiao X, Rothwell S, Miller F, et al.
Arthritis Rheumatol
. 2024 Dec;
PMID: 39679859
Objective: Idiopathic inflammatory myopathies (IIMs, myositis) are rare systemic autoimmune disorders that lead to muscle inflammation, weakness, and extramuscular manifestations, with a strong genetic component influencing disease development and progression....
7.
Pizzamiglio C, Stefanetti R, McFarland R, Thomas N, Ransley G, Hugerth M, et al.
Brain
. 2024 Dec;
148(1):39-46.
PMID: 39657714
Over the past two decades there has been increased interest in orphan drug development for rare diseases. However, hurdles to clinical trial design for these disorders remain. This phase 1a/1b...
8.
Koohi N, Holmes S, Male A, Bamiou D, Dudziec M, Ramdharry G, et al.
Brain Commun
. 2024 Nov;
6(6):fcae374.
PMID: 39584158
Primary mitochondrial diseases, with diverse systemic manifestations, often present with auditory impairments due to mitochondrial dysfunction. This study provides an in-depth exploration of auditory deficits in primary mitochondrial diseases, highlighting...
9.
Sisodiya S, Maslin M, Romanello M, Hanna M
Lancet Neurol
. 2024 Nov;
23(12):1186-1187.
PMID: 39577913
No abstract available.
10.
Frezatti R, Tomaselli P, Record C, Wilson L, Alves G, Dominik N, et al.
Brain Commun
. 2024 Nov;
6(6):fcae342.
PMID: 39544699
Neuromuscular disorders affect almost 20 million people worldwide. Advances in molecular diagnosis have provided valuable insights into neuromuscular disorders, allowing for improved standards of care and targeted therapeutic approaches. Despite...